John Quinn

3.5k total citations
70 papers, 2.4k citations indexed

About

John Quinn is a scholar working on Hematology, Genetics and Spectroscopy. According to data from OpenAlex, John Quinn has authored 70 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 18 papers in Genetics and 18 papers in Spectroscopy. Recurrent topics in John Quinn's work include Mass Spectrometry Techniques and Applications (18 papers), Analytical Chemistry and Chromatography (17 papers) and Multiple Myeloma Research and Treatments (12 papers). John Quinn is often cited by papers focused on Mass Spectrometry Techniques and Applications (18 papers), Analytical Chemistry and Chromatography (17 papers) and Multiple Myeloma Research and Treatments (12 papers). John Quinn collaborates with scholars based in Ireland, United States and United Kingdom. John Quinn's co-authors include Alan G. Marshall, Christopher L. Hendrickson, Nathan K. Kaiser, Greg T. Blakney, Steven C. Beu, Fred W. McLafferty, Michael W. Senko, Tanner Schaub, Michael J. Chalmers and Melinda A. McFarland and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Nature Communications.

In The Last Decade

John Quinn

63 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Quinn Ireland 25 1.2k 610 400 234 224 70 2.4k
John Marshall Canada 32 950 0.8× 1.3k 2.1× 552 1.4× 71 0.3× 157 0.7× 161 4.0k
Barry L. Sharp United Kingdom 28 701 0.6× 364 0.6× 942 2.4× 246 1.1× 245 1.1× 83 2.8k
Dmitry Bandura Canada 23 1.1k 0.9× 1.5k 2.5× 995 2.5× 163 0.7× 49 0.2× 28 3.6k
Andreas Prange Germany 30 792 0.7× 364 0.6× 1.0k 2.6× 142 0.6× 58 0.3× 79 2.9k
Stefan Krämer Germany 29 498 0.4× 310 0.5× 135 0.3× 289 1.2× 99 0.4× 159 3.0k
А. С. Кононихин Russia 29 836 0.7× 940 1.5× 268 0.7× 46 0.2× 53 0.2× 238 2.8k
Stone D.‐H. Shi United States 16 1.2k 1.0× 711 1.2× 254 0.6× 140 0.6× 144 0.6× 35 1.8k
Mark M. Ross United States 35 2.1k 1.7× 2.3k 3.7× 221 0.6× 297 1.3× 56 0.3× 84 5.0k
Beatriz Fernández Spain 27 658 0.5× 256 0.4× 873 2.2× 496 2.1× 447 2.0× 106 2.3k
Helmut Lindner Germany 25 284 0.2× 131 0.2× 453 1.1× 183 0.8× 432 1.9× 47 1.8k

Countries citing papers authored by John Quinn

Since Specialization
Citations

This map shows the geographic impact of John Quinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Quinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Quinn more than expected).

Fields of papers citing papers by John Quinn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Quinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Quinn. The network helps show where John Quinn may publish in the future.

Co-authorship network of co-authors of John Quinn

This figure shows the co-authorship network connecting the top 25 collaborators of John Quinn. A scholar is included among the top collaborators of John Quinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Quinn. John Quinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Swan, Dawn, Claire Comerford, & John Quinn. (2023). Venous thromboembolism in multiple myeloma: Increasing evidence in support of direct oral anticoagulants. British Journal of Haematology. 203(3). 351–352. 1 indexed citations
2.
Quinn, John, et al.. (2023). Genetic Abnormalities in Extramedullary Multiple Myeloma. International Journal of Molecular Sciences. 24(14). 11259–11259. 8 indexed citations
3.
Swan, Dawn, Robert B. Henderson, John Quinn, et al.. (2022). CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Clinical Lymphoma Myeloma & Leukemia. 22(11). 847–852. 1 indexed citations
4.
Comerford, Claire, Siobhán Glavey, John Quinn, & Jamie M. O’Sullivan. (2022). The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies. Journal of Thrombosis and Haemostasis. 20(8). 1766–1777. 27 indexed citations
5.
Comerford, Claire, Siobhán Glavey, Jamie M. O’Sullivan, & John Quinn. (2022). Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma. Cancer Drug Resistance. 2 indexed citations
6.
MacEneaney, Owen J., et al.. (2020). Lysozyme‐induced nephropathy: a rare manifestation of chronic myelomonocytic leukaemia. British Journal of Haematology. 189(3). 393–393. 8 indexed citations
7.
Brodie, R.R., Stephen E. Langabeer, John Quinn, Máirín E. McMenamin, & Patrick Hayden. (2019). Sorafenib for relapsed FLT3‐ITD‐positive acute myeloid leukemia postallogeneic stem cell transplantation presenting as leukemia cutis. SHILAP Revista de lepidopterología. 7(12). 2579–2580. 2 indexed citations
8.
Glavey, Siobhán, et al.. (2019). Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma. Experimental Hematology and Oncology. 8(1). 4–4. 6 indexed citations
9.
10.
Dhami, Sukhraj Pal Singh, Csaba Ortutay, Anna McCormick, et al.. (2018). Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML. Scientific Reports. 8(1). 15752–15752. 22 indexed citations
11.
Langabeer, Stephen E., et al.. (2017). Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. Clinical & Translational Oncology. 20(3). 420–423. 17 indexed citations
12.
13.
Moore, Margaret, et al.. (2017). From a DOAC to Warfarin: Reasons Why Patients Switch. Blood. 130. 4910–4910.
14.
McHugh, Deaglan Joseph, John Quinn, Patrick Thornton, et al.. (2016). Prevalence, clinico-pathological features and outcomes of ‘double-hit’ high-grade B-cell non-Hodgkins lymphoma (NHL): a single institution experience. Annals of Oncology. 27. vi315–vi315. 1 indexed citations
15.
Marcondes, Mary, Alexander Welker Biondo, Rafael Felipe da Costa Vieira, et al.. (2010). Validation of a Leishmania infantum ELISA rapid test for serological diagnosis of Leishmania chagasi in dogs. Veterinary Parasitology. 175(1-2). 15–19. 38 indexed citations
16.
Austen, Belinda, Giancarlo Barone, Anne Reiman, et al.. (2008). Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients. British Journal of Haematology. 142(6). 925–933. 19 indexed citations
17.
Redmond, T. Michael, et al.. (2007). Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn’s disease after immunosuppressive therapy. Journal of Clinical Pathology. 60(1). 80–81. 33 indexed citations
18.
Swords, Ronan, et al.. (2005). CML clonal evolution with resistance to single agent imatinib therapy. Clinical & Laboratory Haematology. 27(5). 347–349. 9 indexed citations
19.
Carey, Luke C., Carmel M. Hawley, Burke Jf, et al.. (1991). EARLY ISCHEMIC CARDIAC MORTALITY IN ELDERLY RENAL-ALLOGRAFT RECIPIENTS. Kidney International. 40(3). 564–564. 2 indexed citations
20.
King, Denis R., Jorge E. Ortega, John Campbell, et al.. (1991). The surgical management of children with incompletely resected hepatic cancer is facilitated by intensive chemotherapy. Journal of Pediatric Surgery. 26(9). 1074–1081. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John Marshall Breakdown of academic impact, for papers by Barry L. Sharp Breakdown of academic impact, for papers by Dmitry Bandura Breakdown of academic impact, for papers by Andreas Prange Breakdown of academic impact, for papers by Stefan Krämer Breakdown of academic impact, for papers by А. С. Кононихин Breakdown of academic impact, for papers by Stone D.‐H. Shi Breakdown of academic impact, for papers by Mark M. Ross Breakdown of academic impact, for papers by Beatriz Fernández Breakdown of academic impact, for papers by Helmut Lindner
Rankless by CCL
2026